

Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference

Iris Bincovich, CEO will participate on the "CBD Treatments" discussion panel on Monday June 14 at 11:00AM ET.

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it will participate at the Lytham Partners Summer 2021 Investor Conference on June 14 through June 16, 2021. Iris Bincovich, CEO of Innocan will participate on the "CBD Treatments" discussion panel alongside representatives from cbdMD, Charlotte's Web, CV Science Inc, and Avicanna on Monday June 14 at 11:00AM ET. A webcast of the presentation will be available on Innocan's website at <https://innocanpharma.com/investors/> or <https://wsw.com/webcast/lytham/panel1/2188879>. The webcast will also be archived and available for replay following the live event. Management will also be participating in virtual one-on-one meetings throughout the event, which run from June 14 through June 16, 2021. To arrange a meeting, please contact Lytham Partners at 1x1@lythampartners.com.

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD"). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+972-54-3012842

info@innocanpharma.com

Lytham Partners, LLC

Ben Shamsian

New York | Phoenix

Telephone: 646-829-9701

shamsian@lythampartners.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information and statements set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, are forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively "forward-looking information"). By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the therapeutic applications resulting from research activities, the range of clinical applications and outcomes that may result, , the potential to address certain health conditions, the potential benefits of CDB loaded exsomes, the benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers.



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/87098>